Loading
JT
Juno Therapeutics, Inc. Stock: price and insider trades · United States
Juno Therapeutics, Inc.: what insiders have been doing
Juno Therapeutics, Inc. is a listed company. Filings by its managers are published through SEC (Form 4). Juno Therapeutics, Inc. has had no insider filing for more than a year; the last one goes back to 20 January 2016.
Other companies in the same market with recent insider buying flagged by our signals: Relmada Therapeutics, Inc. and Uber Technologies, Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
2
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
2 ops. · all time
Last declaration on 20 January 2016
Declarations2 total
2,400 sharesCommon StockSEC:0000899243-16-011990:0
800 sharesCommon StockSEC:0000899243-16-011990:1
2 of 2 declarations
About Juno Therapeutics, Inc.
Juno Therapeutics, Inc. is a biopharmaceutical company focused on developing cellular therapies for cancer treatment. It specializes in T cell-based treatments and gene therapies.
